Parkinson's Disease Study

Protocol Title

An Open-Label, Phase 2 Study to Assess the Safety and Efficacy of 99mTc-NC100697 Injection in Detecting or Excluding Striatal Dopaminergic Deficits in Subjects With 1 or More Signs of a Parkinsonian Syndrome

Principal Investigator

Alan Waxman, MD

IRB Approval Number


Medical Specialty Area



Patients with tremor and suspected Parkinson's Disease

IRB Approval Expiration Date

5/31/07 (continuation has been submitted)

The study is ongoing, and patients are undergoing follow up, but enrollment to new subjects is closed.

Contact Information

Jessica Lee (Study Coordinator)
Phone: (310) 423-7546
Send Us a Message
Android app on Google Play